We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
PerkinElmer Inc | NYSE:PKI | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 115.24 | 0 | 01:00:00 |
PerkinElmer, Inc. (NYSE: PKI), a global leader focused on improving the health and safety of people and the environment, today reported financial results for the third quarter ended October 4, 2015.
The Company reported GAAP earnings per share from continuing operations of $0.48, compared to $0.38 in the third quarter of 2014. Revenue in the third quarter of 2015 was $563.4 million, compared to $542.0 million in the third quarter of 2014. GAAP operating income from continuing operations for the third quarter of 2015 was $75.9 million, compared to $58.8 million in the third quarter of 2014. GAAP operating profit margin from continuing operations was 13.5% in the third quarter of 2015, compared to 10.8% in the third quarter of 2014.
Adjusted earnings per share was $0.60, compared to $0.57 in the third quarter of 2014. Adjusted revenue increased 4% and organic revenue increased 6%, compared to the third quarter of 2014. Adjusted revenue was $563.6 million, compared to $542.9 million in the third quarter of 2014. Adjusted operating income for the third quarter of 2015 was $95.7 million, compared to $91.3 million for the same period a year ago. Adjusted operating profit margin was 17.0% as a percentage of adjusted revenue, as compared to 16.8% for the same period a year ago. Adjustments for the Company's non-GAAP financial measures have been noted in the attached reconciliations. Certain of these non-GAAP financial measures are presented on a ‘constant currency’ basis, so that financial results can be viewed without the effects of fluctuations in foreign currency exchange rates, allowing for a period-to-period comparison of underlying business performance.
“I am pleased to report another solid quarterly performance as we delivered strong and broad-based revenue growth and profitability despite a somewhat mixed global macro-environment,” said Robert Friel, chairman and chief executive officer of PerkinElmer. “We continue to believe that the strength and differentiation of PerkinElmer’s products and solutions coupled with a relentless focus on executing against our strategic priorities will afford us the ability to deliver on our balance of year commitments and position us well for 2016 and beyond.”
Financial Overview by Reporting Segment for the Third Quarter 2015
Human Health
Environmental Health
Financial Guidance – Full Year 2015 - Updated
For the full year 2015, the Company now forecasts GAAP earnings per share from continuing operations in the range of $2.02 to $2.05 and on a non-GAAP basis, which is expected to include the adjustments noted in the attached reconciliation, adjusted earnings per share in the range of $2.56 to $2.59 representing 13-14% constant currency adjusted earnings per share growth.
Conference Call Information
The Company will discuss its third quarter results and its outlook for business trends in a conference call on November 5, 2015 at 5:00 p.m. Eastern Time (ET). To access the call, please dial (541) 797-2422 prior to the scheduled conference call time and provide the access code 49211111.
A live audio webcast of the call will be available on the Investors section of the Company’s Web site, www.perkinelmer.com. Please go to the site at least 15 minutes prior to the call in order to register, download, and install any necessary software. An archived version of the webcast will be posted on the Company’s Web site for a two week period beginning approximately two hours after the call.
Use of Non-GAAP Financial Measures
In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this earnings announcement also contains non-GAAP financial measures. The reasons that we use these measures, a reconciliation of these measures to the most directly comparable GAAP measures, and other information relating to these measures are included below following our GAAP financial statements.
Factors Affecting Future Performance
This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, plans concerning business development opportunities and divestitures and effects of foreign currency exchange rates. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) fluctuations in the global economic and political environments; (3) our failure to introduce new products in a timely manner; (4) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable, or successfully divest businesses; (5) our failure to adequately protect our intellectual property; (6) the loss of any of our licenses or licensed rights; (7) our ability to compete effectively; (8) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (9) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (10) disruptions in the supply of raw materials and supplies; (11) the manufacture and sale of products exposing us to product liability claims; (12) our failure to maintain compliance with applicable government regulations; (13) regulatory changes; (14) our failure to comply with healthcare industry regulations; (15) economic, political and other risks associated with foreign operations, including significant fluctuations in foreign currency exchange rates; (16) our ability to retain key personnel; (17) significant disruption in our information technology systems; (18) our ability to obtain future financing; (19) restrictions in our credit agreements; (20) our ability to realize the full value of our intangible assets; (21) significant fluctuations in our stock price; (22) reduction or elimination of dividends on our common stock; and (23) other factors which we describe under the caption "Risk Factors" in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
About PerkinElmer
PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately $2.2 billion in 2014, has about 7,700 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.
PerkinElmer, Inc. and SubsidiariesCONDENSED CONSOLIDATED INCOME STATEMENTSThree Months Ended
Nine Months Ended
(In thousands, except per share data)October 4, 2015
September 28, 2014
October 4, 2015
September 28, 2014
Revenue $ 563,436 $ 542,049 $ 1,654,243 $ 1,628,829 Cost of revenue 308,833 298,740 911,754 901,823 Selling, general and administrative expenses 147,728 142,997 440,343 442,687 Research and development expenses 31,095 30,444 95,898 90,175 Restructuring and contract termination charges, net (118 ) 11,092 4,838 13,969 Operating income from continuing operations 75,898 58,776 201,410 180,175 Interest income (147 ) (130 ) (488 ) (375 ) Interest expense 9,874 8,909 28,564 27,207 Other expense, net 2,217 2,187 4,132 4,387 Income from continuing operations, before income taxes 63,954 47,810 169,202 148,956 Provision for income taxes 9,057 4,912 24,998 19,104 Income from continuing operations 54,897 42,898 144,204 129,852 Gain (loss) from discontinued operations, before income taxes 8 (1,091 ) 6 (4,205 ) Loss on disposition of discontinued operations, before income taxes (3 ) (7 ) (26 ) (381 ) Provision for (benefit from) income taxes on discontinued operations and dispositions 39 (477 ) 13 (1,725 ) Loss from discontinued operations and dispositions (34 ) (621 ) (33 ) (2,861 ) Net income $ 54,863 $ 42,277 $ 144,171 $ 126,991 Diluted earnings per share: Income from continuing operations $ 0.48 $ 0.38 $ 1.27 $ 1.14 Loss from discontinued operations and dispositions (0.00 ) (0.01 ) (0.00 ) (0.03 ) Net income $ 0.48 $ 0.37 $ 1.27 $ 1.12 Weighted average diluted shares of common stock outstanding 113,422 113,759 113,565 113,836 ABOVE PREPARED IN ACCORDANCE WITH GAAP Additional Supplemental Information (1): (per share, continuing operations) GAAP EPS from continuing operations $ 0.48 $ 0.38 $ 1.27 $ 1.14 Amortization of intangible assets, net of income taxes 0.11 0.11 0.34 0.35 Purchase accounting adjustments, net of income taxes 0.01 0.00 0.05 0.00 Significant litigation matter, net of income taxes - - - 0.04 Mark to market on postretirement benefits, net of income taxes - - 0.01 (0.00 ) Restructuring and contract termination charges, net of income taxes (0.00 ) 0.07 0.03 0.09 Adjusted EPS $ 0.60 $ 0.57 $ 1.70 $ 1.62 (1) amounts may not sum due to roundingPerkinElmer, Inc. and SubsidiariesREVENUE AND OPERATING INCOME (LOSS)
Three Months Ended
Nine Months Ended
(In thousands, except percentages)October 4, 2015
September 28, 2014
October 4, 2015
September 28, 2014
Human Health Reported revenue$
343,636
$
336,949
$
1,011,177
$
1,009,525
Purchase accounting adjustments 164 811 628 2,689Adjusted revenue
343,800 337,760 1,011,805 1,012,214 Reported operating income from continued operations 63,147 48,089 179,560 149,979 OP% 18.4 % 14.3 % 17.8 % 14.9 % Amortization of intangible assets 15,298 18,402 46,041 54,710 Purchase accounting adjustments 195 836 720 2,037 Acquisition-related costs 74 18 283 87 Restructuring and contract termination charges, net 184 6,285 2,004 7,140 Adjusted operating income 78,898 73,630 228,608 213,953 Adjusted OP% 22.9 % 21.8 % 22.6 % 21.1 % Environmental Health Reported revenue 219,800 205,100 643,066 619,304 Reported operating income from continued operations 22,838 18,540 53,606 65,725 OP% 10.4 % 9.0 % 8.3 % 10.6 % Amortization of intangible assets 3,551 2,177 12,499 7,140 Purchase accounting adjustments 808 - 7,275 (830 ) Acquisition-related costs 19 17 235 129 Restructuring and contract termination charges, net (302 ) 4,807 2,834 6,829 Adjusted operating income 26,914 25,541 76,449 78,993 Adjusted OP% 12.2 % 12.5 % 11.9 % 12.8 % Corporate Reported operating loss (10,087 ) (7,853 ) (31,756 ) (35,529 ) Significant litigation matter - - - 6,645 Mark to market on postretirement benefits - - 1,066 (54 ) Adjusted operating loss (10,087 ) (7,853 ) (30,690 ) (28,938 ) Continuing Operations Reported revenue$
563,436
$
542,049
$
1,654,243
$
1,628,829
Purchase accounting adjustments 164 811 628 2,689Adjusted revenue
563,600 542,860 1,654,871 1,631,518 Reported operating income from continued operations 75,898 58,776 201,410 180,175 OP% 13.5 % 10.8 % 12.2 % 11.1 % Amortization of intangible assets 18,849 20,579 58,540 61,850 Purchase accounting adjustments 1,003 836 7,995 1,207 Acquisition-related costs 93 35 518 216 Significant litigation matter - - - 6,645 Mark to market on postretirement benefits - - 1,066 (54 ) Restructuring and contract termination charges, net (118 ) 11,092 4,838 13,969 Adjusted operating income$
95,725
$
91,318
$
274,367
$
264,008
Adjusted OP% 17.0 % 16.8 % 16.6 % 16.2 % REPORTED REVENUE AND REPORTED OPERATING INCOME (LOSS) PREPARED IN ACCORDANCE WITH GAAPPerkinElmer, Inc. and SubsidiariesCONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) October 4, 2015 December 28, 2014 Current assets: Cash and cash equivalents $ 195,066 $ 174,821 Accounts receivable, net 414,193 470,563 Inventories 313,047 285,457 Other current assets 151,531 137,710 Total current assets 1,073,837 1,068,551 Property, plant and equipment: At cost 494,768 492,814 Accumulated depreciation (330,591 ) (316,620 ) Property, plant and equipment, net 164,177 176,194 Marketable securities and investments 1,574 1,568 Intangible assets, net 424,239 490,265 Goodwill 2,253,943 2,284,077 Other assets, net 113,897 113,420 Total assets $ 4,031,667 $ 4,134,075 Current liabilities: Current portion of long-term debt $ 1,107 $ 1,075 Accounts payable 149,684 173,953 Short-term accrued restructuring and contract termination charges 12,111 17,124 Accrued expenses and other current liabilities 389,274 403,021 Current liabilities of discontinued operations 2,100 2,137 Total current liabilities 554,276 597,310 Long-term debt 1,027,269 1,051,892 Long-term liabilities 395,798 442,771 Total liabilities 1,977,343 2,091,973 Total stockholders' equity 2,054,324 2,042,102 Total liabilities and stockholders' equity $ 4,031,667 $ 4,134,075 PREPARED IN ACCORDANCE WITH GAAP
PerkinElmer, Inc. and SubsidiariesCONSOLIDATED STATEMENTS OF CASH FLOWS
Three Months Ended
Nine Months Ended
October 4,2015
September28, 2014
October 4,2015
September 28,2014
(In thousands) Operating activities: Net income $ 54,863 $ 42,277 $ 144,171 $ 126,991 Loss from discontinued operations and dispositions, net of income taxes 34 621 33 2,861 Income from continuing operations 54,897 42,898 144,204 129,852 Adjustments to reconcile income from continuing operations to net cash provided by continuing operations: Stock-based compensation 4,290 2,450 12,483 11,769 Restructuring and contract termination charges, net (118 ) 11,092 4,838 13,969 Amortization of deferred debt issuance costs and accretion of discounts 435 409 1,112 1,071 Depreciation and amortization 27,164 28,926 83,757 86,833 Amortization of acquired inventory revaluation 808 - 7,275 - Changes in operating assets and liabilities which provided (used) cash, excluding effects from companies purchased and divested: Accounts receivable, net 5,518 3,407 36,361 26,841Inventories
(17,497 ) (12,799 ) (50,824 ) (28,536 ) Accounts payable (18,375 ) 7,858 (19,916 ) (4,009 ) Accrued expenses and other 3,646 (21,154 ) (57,361 ) (52,133 ) Net cash provided by operating activities of continuing operations 60,768 63,087 161,929 185,657 Net cash used in operating activities of discontinued operations (43 ) (160 ) (70 ) (624 ) Net cash provided by operating activities 60,725 62,927 161,859 185,033 Investing activities: Capital expenditures (7,715 ) (7,767 ) (17,814 ) (22,214 ) Proceeds from surrender of life insurance policies 757 65 757 490 Changes in restricted cash balances - - 59 - Activity related to acquisitions and investments, net of cash and cash equivalents acquired - (1,529 ) (18,735 ) (1,879 ) Net cash used in investing activities of continuing operations (6,958 ) (9,231 ) (35,733 ) (23,603 ) Net cash used in investing activities of discontinued operations - - - (213 ) Net cash used in investing activities (6,958 ) (9,231 ) (35,733 ) (23,816 ) Financing Activities: Payments on revolving credit facility (122,000 ) (73,000 ) (371,000 ) (305,000 ) Proceeds from revolving credit facility 163,000 34,000 347,000 227,000 Payments of debt issuance costs - - - (1,845 ) Settlement of hedges (4,258 ) - 19,210 - Net payments on other credit facilities (1,144 ) (718 ) (800 ) (1,225 ) Payments for acquisition-related contingent consideration (26 ) (855 ) (26 ) (855 ) Proceeds from issuance of common stock under stock plans 412 1,493 13,081 20,947 Purchases of common stock (72,063 ) (28 ) (76,158 ) (39,004 ) Dividends paid (7,938 ) (7,904 ) (23,737 ) (23,713 ) Net cash used in financing activities (44,017 ) (47,012 ) (92,430 ) (123,695 ) Effect of exchange rate changes on cash and cash equivalents (6,854 ) (8,259 ) (13,451 ) (7,081 ) Net increase (decrease) in cash and cash equivalents 2,896 (1,575 ) 20,245 30,441 Cash and cash equivalents at beginning of period 192,170 205,258 174,821 173,242 Cash and cash equivalents at end of period $ 195,066 $ 203,683 $ 195,066 $ 203,683 PREPARED IN ACCORDANCE WITH GAAPPerkinElmer, Inc. and SubsidiariesRECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (1) (In millions, except per share data and percentages)
PKI
Three Months EndedOctober 4, 2015
September 28, 2014
Adjusted revenue: Revenue $ 563.4 $ 542.0 Purchase accounting adjustments 0.2 0.8 Adjusted revenue $ 563.6 $ 542.9 Adjusted gross margin: Gross margin $ 254.6 45.2 % $ 243.3 44.9 % Amortization of intangible assets 10.7 1.9 % 12.4 2.3 % Purchase accounting adjustments 1.0 0.2 % 0.8 0.2 % Adjusted gross margin $ 266.3 47.2 % $ 256.5 47.3 % Adjusted SG&A: SG&A $ 147.7 26.2 % $ 143.0 26.4 % Amortization of intangible assets (8.0 ) -1.4 % (8.0 ) -1.5 % Purchase accounting adjustments (0.0 ) 0.0 % (0.0 ) 0.0 % Acquisition-related costs (0.1 ) 0.0 % (0.0 ) 0.0 % Adjusted SG&A $ 139.6 24.8 % $ 134.9 24.9 % Adjusted R&D: R&D $ 31.1 5.5 % $ 30.4 5.6 % Amortization of intangible assets (0.1 ) 0.0 % (0.2 ) 0.0 % Adjusted R&D $ 31.0 5.5 % $ 30.3 5.6 % Adjusted operating income: Operating income $ 75.9 13.5 % $ 58.8 10.8 % Amortization of intangible assets 18.8 3.3 % 20.6 3.8 % Purchase accounting adjustments 1.0 0.2 % 0.8 0.2 % Acquisition-related costs 0.1 0.0 % 0.0 0.0 % Restructuring and contract termination charges, net (0.1 ) 0.0 % 11.1 2.0 % Adjusted operating income $ 95.7 17.0 % $ 91.3 16.8 %PKI
Three Months Ended October 4, 2015 September 28, 2014 Adjusted EPS: GAAP EPS $ 0.48 $ 0.37 Discontinued operations, net of income taxes (0.00 ) (0.01 ) GAAP EPS from continuing operations 0.48 0.38 Amortization of intangible assets, net of income taxes 0.11 0.11 Purchase accounting adjustments, net of income taxes 0.01 0.00 Acquisition-related costs, net of income taxes 0.00 0.00 Restructuring and contract termination charges, net of income taxes (0.00 ) 0.07 Adjusted EPS $ 0.60 $ 0.57PKI
Three Months Ended October 4, 2015 September 28, 2014Impact of tax Expense related to non-gaap adjustments on adjusted EPS:
Amortization of intangible assets
$
(0.06 )$
(0.07 )Purchase accounting adjustments
(0.00 ) (0.00 )Acquisition-related costs
(0.00 ) (0.00 )Restructuring and contract termination charges
0.00 (0.03 ) Impact of tax expense related to non-gaap adjustments on adjusted EPS $ (0.06 ) $ (0.09 )PKI
Three Months Ended October 4, 2015 September 28, 2014 Constant currency adjusted EPS: GAAP EPS $ 0.48 $ 0.37 Discontinued operations, net of income taxes (0.00 ) (0.01 ) GAAP EPS from continuing operations 0.48 0.38 Amortization of intangible assets, net of income taxes 0.11 0.11 Purchase accounting adjustments, net of income taxes 0.01 0.00 Acquisition-related costs, net of income taxes 0.00 0.00 Restructuring and contract termination charges, net of income taxes (0.00 ) 0.07 Effect of currency changes from prior year period 0.06 - Constant currency adjusted EPS $ 0.66 $ 0.57PKI
Three Months Ended October 4, 2015 September 28, 2014 Tax Expense related to non-gaap adjustments on constant currency adjusted EPS:Amortization of intangible assets
$
(0.06 )$
(0.07 )Purchase accounting adjustments
(0.00 ) (0.00 )Acquisition-related costs
(0.00 ) (0.00 )Restructuring and contract termination charges
0.00 (0.03 ) Effect of currency changes from prior year period (0.01 ) - Impact of tax expense related to non-gaap adjustments on constant currency adjusted EPS $ (0.07 ) $ (0.09 )Human Health
Three Months Ended October 4, 2015 September 28, 2014 Adjusted revenue: Revenue $ 343.6 $ 336.9 Purchase accounting adjustments 0.2 0.8 Adjusted revenue $ 343.8 $ 337.8 Adjusted operating income: Operating income $ 63.1 18.4 % $ 48.1 14.3 % Amortization of intangible assets 15.3 4.5 % 18.4 5.5 % Purchase accounting adjustments 0.2 0.1 % 0.8 0.2 % Acquisition-related costs 0.1 0.0 % 0.0 0.0 % Restructuring and contract termination charges, net 0.2 0.1 % 6.3 1.9 % Adjusted operating income $ 78.9 22.9 % $ 73.6 21.8 %Environmental Health
Three Months Ended October 4, 2015 September 28, 2014 Revenue: Revenue $ 219.8 $ 205.1 Adjusted operating income: Operating income $ 22.8 10.4 % $ 18.5 9.0 % Amortization of intangible assets 3.6 1.6 % 2.2 1.1 % Purchase accounting adjustments 0.8 0.4 % - 0.0 % Acquisition-related costs 0.0 0.0 % 0.0 0.0 % Restructuring and contract termination charges, net (0.3 ) -0.1 % 4.8 2.3 % Adjusted operating income $ 26.9 12.2 % $ 25.5 12.5 % (1) amounts may not sum due to roundingPerkinElmer, Inc. and SubsidiariesRECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (1) (In millions, except per share data and percentages) PKI Nine Months Ended
October 4, 2015
September 28, 2014
Adjusted revenue: Revenue $ 1,654.2 $ 1,628.8 Purchase accounting adjustments 0.6 2.7 Adjusted revenue $ 1,654.9 $ 1,631.5 Adjusted gross margin: Gross margin $ 742.5 44.9 % $ 727.0 44.6 % Amortization of intangible assets 32.2 1.9 % 37.4 2.3 % Purchase accounting adjustments 7.9 0.5 % 2.7 0.2 % Mark to market on postretirement benefits 0.2 0.0 % (0.1 ) 0.0 % Adjusted gross margin $ 782.9 47.3 % $ 767.1 47.0 % Adjusted SG&A: SG&A $ 440.3 26.6 % $ 442.7 27.2 % Amortization of intangible assets (26.0 ) -1.6 % (24.0 ) -1.5 % Purchase accounting adjustments (0.0 ) 0.0 % 1.5 0.1 % Acquisition-related costs (0.5 ) 0.0 % (0.2 ) 0.0 % Significant litigation matter - 0.0 % (6.6 ) -0.4 % Mark to market on postretirement benefits (0.8 ) -0.1 % - 0.0 % Adjusted SG&A $ 413.0 25.0 % $ 413.4 25.3 % Adjusted R&D: R&D $ 95.9 5.8 % $ 90.2 5.5 % Amortization of intangible assets (0.4 ) 0.0 % (0.4 ) 0.0 % Adjusted R&D $ 95.5 5.8 % $ 89.7 5.5 % Adjusted operating income: Operating income $ 201.4 12.2 % $ 180.2 11.1 % Amortization of intangible assets 58.5 3.5 % 61.9 3.8 % Purchase accounting adjustments 8.0 0.5 % 1.2 0.1 % Acquisition-related costs 0.5 0.0 % 0.2 0.0 % Significant litigation matter - 0.0 % 6.6 0.4 % Mark to market on postretirement benefits 1.1 0.1 % (0.1 ) 0.0 % Restructuring and contract termination charges, net 4.8 0.3 % 14.0 0.9 % Adjusted operating income $ 274.4 16.6 % $ 264.0 16.2 % PKI Nine Months EndedOctober 4, 2015
September 28, 2014
Adjusted EPS: GAAP EPS $ 1.27 $ 1.12 Discontinued operations, net of income taxes (0.00 ) (0.03 ) GAAP EPS from continuing operations 1.27 1.14 Amortization of intangible assets, net of income taxes 0.34 0.35 Purchase accounting adjustments, net of income taxes 0.05 0.00 Significant litigation matter, net of income taxes - 0.04 Acquisition-related costs, net of income taxes 0.00 0.00 Mark to market on postretirement benefits, net of income taxes 0.01 (0.00 ) Restructuring and contract termination charges, net of income taxes 0.03 0.09 Adjusted EPS $ 1.70 $ 1.62 PKI Nine Months EndedOctober 4, 2015
September 28, 2014
Impact of tax Expense related to non-gaap adjustments on adjusted EPS:Amortization of intangible assets
$
(0.18 )$
(0.19 )Purchase accounting adjustments
(0.00 ) (0.00 )Significant litigation matter
- (0.02 )Acquisition-related costs
(0.02 ) (0.01 )Mark to market on postretirement benefits
(0.00 ) 0.00Restructuring and contract termination charges
(0.01 ) (0.03 ) Impact of tax expense related to non-gaap adjustments on adjusted EPS $ (0.22 ) $ (0.26 ) PKI Twelve Months EndedJanuary 3, 2016
Adjusted EPS:Projected
GAAP EPS from continuing operations $ 2.02 - $2.05 Amortization of intangible assets, net of income taxes 0.45 Purchase accounting adjustments, net of income taxes 0.05 Mark to market on postretirement benefits, net of income taxes 0.01 Restructuring and contract termination charges, net of income taxes 0.03 Adjusted EPS $ 2.56 - $2.59 PKI Twelve Months EndedJanuary 3, 2016
Constant Currency Adjusted EPS: Projected GAAP EPS from continuing operations $ 2.02 - $2.05 Amortization of intangible assets, net of income taxes 0.45 Purchase accounting adjustments, net of income taxes 0.05 Mark to market on postretirement benefits, net of income taxes 0.01 Restructuring and contract termination charges, net of income taxes 0.03 Effect of currency changes from prior year period 0.23 Adjusted EPS $ 2.79 - $2.82 Human Health Nine Months EndedOctober 4, 2015
September 28, 2014
Adjusted revenue: Revenue $ 1,011.2 $ 1,009.5 Purchase accounting adjustments 0.6 2.7 Adjusted revenue $ 1,011.8 $ 1,012.2 Adjusted operating income: Operating income $ 179.6 17.8 % $ 150.0 14.9 % Amortization of intangible assets 46.0 4.6 % 54.7 5.4 % Purchase accounting adjustments 0.7 0.1 % 2.0 0.2 % Acquisition-related costs 0.3 0.0 % 0.1 0.0 % Restructuring and contract termination charges, net 2.0 0.2 % 7.1 0.7 % Adjusted operating income $ 228.6 22.6 % $ 214.0 21.1 % Environmental Health Nine Months EndedOctober 4, 2015
September 28, 2014
Revenue: Revenue $ 643.1 $ 619.3 Adjusted operating income: Operating income $ 53.6 8.3 % $ 65.7 10.6 % Amortization of intangible assets 12.5 1.9 % 7.1 1.2 % Purchase accounting adjustments 7.3 1.1 % (0.8 ) -0.1 % Acquisition-related costs 0.2 0.0 % 0.1 0.0 % Restructuring and contract termination charges, net 2.8 0.4 % 6.8 1.1 % Adjusted operating income $ 76.4 11.9 % $ 79.0 12.8 % (1) amounts may not sum due to roundingPerkinElmer, Inc. and SubsidiariesRECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (1)
PKI
Three Months EndedOctober 4, 2015
Organic revenue growth: Reported revenue growth 4 % Less: effect of foreign exchange rates -6 % Less: effect of acquisitions including purchase accounting adjustments 4 % Organic revenue growth 6 %Human Health
Three Months EndedOctober 4, 2015
Organic revenue growth: Reported revenue growth 2 % Less: effect of foreign exchange rates -5 % Less: effect of acquisitions including purchase accounting adjustments 1 % Organic revenue growth 7 %Environmental Health
Three Months EndedOctober 4, 2015
Organic revenue growth: Reported revenue growth 7 % Less: effect of foreign exchange rates -9 % Less: effect of acquisitions including purchase accounting adjustments 11 % Organic revenue growth 5 % (1) amounts may not sum due to rounding
PerkinElmer, Inc. and SubsidiariesQ3 2015 CONSTANT CURRENCY ADJUSTED REVENUE GROWTH
PKI
Three Months EndedOctober 4, 2015
Constant currency adjusted revenue growth:
Reported revenue growth 4 % Less: effect of foreign exchange rates -6 %Constant currency adjusted revenue growth
10 %
Explanation of Non-GAAP Financial Measures
We report our financial results in accordance with GAAP. However, management believes that, in order to properly understand our short-term and long-term financial and operational trends, investors may wish to consider the impact of certain non-cash or non-recurring items, which result from facts and circumstances that vary in frequency and impact on continuing operations. Accordingly, we present non-GAAP financial measures as a supplement to the financial measures we present in accordance with GAAP. These non-GAAP financial measures provide management with additional means to understand and evaluate the operating results and trends in our ongoing business by adjusting for certain non-cash expenses and other items that management believes might otherwise make comparisons of our ongoing business with prior periods more difficult, obscure trends in ongoing operations, or reduce management's ability to make useful forecasts. Management believes these non-GAAP financial measures provide additional means of evaluating period-over-period operating performance. In addition, management understands that some investors and financial analysts find this information helpful in analyzing our financial and operational performance and comparing this performance to our peers and competitors.
We use the term “adjusted revenue” to refer to GAAP revenue, including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules. We use the related term “adjusted revenue growth” to refer to the measure of comparing current period adjusted revenue with the corresponding period of the prior year.
We use the term “constant currency adjusted revenue” to refer to GAAP revenue recalculated using the currency exchange rates for the corresponding period in the prior year, and including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules. We use the related term “constant currency adjusted revenue growth” to refer to the measure of comparing current period constant currency adjusted revenue with the corresponding period of the prior year.
We use the term “organic revenue” to refer to GAAP revenue, excluding the effect of foreign currency translation and acquisitions, and including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules. We use the related term “organic revenue growth” to refer to the measure of comparing current period organic revenue with the corresponding period of the prior year.
We use the term “adjusted gross margin” to refer to GAAP gross margin, excluding amortization of intangible assets, inventory fair value adjustments related to business acquisitions, and including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to business combination accounting rules. We also exclude adjustments for mark-to-market accounting on post-retirement benefits, therefore only our projected costs have been used to calculate our non-GAAP measure. We use the related term “adjusted gross margin percentage” to refer to adjusted gross margin as a percentage of adjusted revenue.
We use the term “adjusted SG&A expense” to refer to GAAP SG&A expense, excluding amortization of intangible assets, purchase accounting adjustments, acquisition-related expenses, and a significant litigation matter. We also exclude adjustments for mark-to-market accounting on post-retirement benefits, therefore only our projected costs have been used to calculate our non-GAAP measure. We use the related term “adjusted SG&A percentage” to refer to adjusted SG&A expense as a percentage of adjusted revenue.
We use the term “adjusted R&D expense” to refer to GAAP R&D expense, excluding amortization of intangible assets. We use the related term “adjusted R&D percentage” to refer to adjusted R&D expense as a percentage of adjusted revenue.
We use the term “adjusted operating income,” to refer to GAAP operating income, including revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules, and excluding amortization of intangible assets, other purchase accounting adjustments, acquisition-related costs, a significant litigation matter, and restructuring and contract termination charges. We also exclude adjustments for mark-to-market accounting on post-retirement benefits, therefore only our projected costs have been used to calculate our non-GAAP measure. We use the related terms “adjusted operating profit percentage,” “adjusted operating profit margin,” or “adjusted operating margin” to refer to adjusted operating income as a percentage of adjusted revenue.
We use the term “adjusted earnings per share,” or “adjusted EPS,” to refer to GAAP earnings per share, including revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules, and excluding discontinued operations, amortization of intangible assets, other purchase accounting adjustments, acquisition-related costs, a significant litigation matter, restructuring and contract termination charges. We also exclude adjustments for mark-to-market accounting on post-retirement benefits, therefore only our projected costs have been used to calculate our non-GAAP measure. We also adjust for any tax impact related to the above items.
We use the term “constant currency adjusted earnings per share,” or “constant currency adjusted EPS,” to refer to GAAP earnings per share recalculated using the currency exchange rates for the corresponding period in the prior year, including revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules, and excluding discontinued operations, amortization of intangible assets, other purchase accounting adjustments, acquisition-related costs, a significant litigation matter, and restructuring and contract termination charges. We also exclude adjustments for mark-to-market accounting on post-retirement benefits, therefore only our projected costs have been used to calculate our non-GAAP measure. We also adjust for any tax impact related to the above items.
Management includes or excludes the effect of each of the items identified below in the applicable non-GAAP financial measure referenced above for the reasons set forth below with respect to that item:
The tax effect for discontinued operations is calculated based on the authoritative guidance in the Financial Accounting Standards Board’s Accounting Standards Codification 740, Income Taxes. The tax effect for amortization of intangible assets, inventory fair value adjustments related to business acquisitions, changes to the fair values assigned to contingent consideration, other costs related to business acquisitions, a significant litigation matter, adjustments for mark-to-market accounting on post-retirement benefits, restructuring and contract termination charges, and the revenue from contracts acquired with various acquisitions is calculated based on operational results and applicable jurisdictional law, which contemplates tax rates currently in effect to determine our tax provision. The tax effect for the impact from foreign currency exchange rates on the current period is calculated based on the average rate currently in effect to determine our tax provision.
The non-GAAP financial measures described above are not meant to be considered superior to, or a substitute for, our financial statements prepared in accordance with GAAP. There are material limitations associated with non-GAAP financial measures because they exclude charges that have an effect on our reported results and, therefore, should not be relied upon as the sole financial measures to evaluate our financial results. Management compensates and believes that investors should compensate for these limitations by viewing the non-GAAP financial measures in conjunction with the GAAP financial measures. In addition, the non-GAAP financial measures included in this earnings announcement may be different from, and therefore may not be comparable to, similar measures used by other companies.
Each of the non-GAAP financial measures listed above are also used by our management to evaluate our operating performance, communicate our financial results to our Board of Directors, benchmark our results against our historical performance and the performance of our peers, evaluate investment opportunities including acquisitions and discontinued operations, and determine the bonus payments for senior management and employees.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151105006799/en/
Investor Relations:PerkinElmer, Inc.Tommy J. Thomas, CPA, 781-663-5889tommy.thomas@perkinelmer.comorMedia Contact:PerkinElmer, Inc.Fara Goldberg, 781-663-5699fara.goldberg@perkinelmer.com
1 Year PerkinElmer Chart |
1 Month PerkinElmer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions